Effectiveness of BA.1-and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

被引：11

作者：

Arashiro, Takeshi ^{[1
,2
,3
,4
]}

Arima, Yuzo ^{[1
]}

Kuramochi, Jin ^{[5
,6
]}

Muraoka, Hirokazu ^{[7
]}

Sato, Akihiro ^{[8
]}

Chubachi, Kumi ^{[9
]}

Yanai, Atsushi ^{[10
]}

Arioka, Hiroko ^{[10
]}

Uehara, Yuki ^{[11
,12
]}

Ihara, Genei ^{[13
]}

Kato, Yasuyuki ^{[14
]}

Yanagisawa, Naoki ^{[15
]}

Ueda, Akihiro ^{[16
]}

Kato, Hideaki ^{[17
]}

Oka, Hideaki ^{[18
]}

Nishida, Yusuke ^{[18
]}

Nidaira, Yuki ^{[5
]}

Asami, Takahiro ^{[19
]}

Jinta, Torahiko ^{[20
]}

Nakamura, Akira ^{[21
]}

Oba, Kunihiro ^{[22
]}

Taniyama, Daisuke ^{[23
]}

Yamamoto, Kei ^{[18
]}

Tanaka, Katsushi ^{[17
]}

Ueshima, Kankuro ^{[24
]}

Fuwa, Tetsuji ^{[24
]}

Stucky, Ashley ^{[1
]}

Suzuki, Tadaki ^{[2
]}

Smith, Chris ^{[3
]}

Hibberd, Martin ^{[3
]}

Ariyoshi, Koya ^{[4
]}

Suzuki, Motoi ^{[1
]}

机构：

[1] Natl Inst Infect Dis, Ctr Surveillance Immunizat & Epidemiol Res, Tokyo, Japan

[2] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan

[3] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England

[4] Nagasaki Univ, Sch Trop Med & Global Hlth, Nagasaki, Japan

[5] Kuramochi Clin Interpk, Tochigi, Japan

[6] Tokyo Med & Dent Univ, Dept Global Hlth Promot, Tokyo, Japan

[7] Clin TAMACHI, Tokyo, Japan

[8] KARADA Internal Med Clin, Tokyo, Japan

[9] Chubachi Internal Resp Med Clin, Tokyo, Japan

[10] St Lukes Int Hosp, Dept Gen Internal Med, Tokyo, Japan

[11] St Lukes Int Hosp, Dept Clin Lab, Tokyo, Japan

[12] Fujita Hlth Univ, Sch Med, Dept Infect Dis, Aichi, Japan

[13] Machida Ekimae Naika Clin, Tokyo, Japan

[14] Int Univ Hlth, Welf Narita Hosp, Dept Infect Dis, Chiba, Japan

[15] Yanagisawa Clin, Tokyo, Japan

[16] Japanese Red Cross Med Ctr, Dept Infect Dis, Tokyo, Japan

[17] Yokohama City Univ Med, Infect Prevent & Control Dept, Yokohama, Japan

[18] Saitama Med Ctr, Dept Gen Internal Med & Infect Dis, Saitama, Japan

[19] Sano Kosei Gen Hosp, Dept Internal Med, Tochigi, Japan

[20] St Lukes Int Hosp, Dept Pulm Med, Tokyo, Japan

[21] Asahi Gen Hosp, Dept Internal Med, Chiba, Japan

[22] Showa Gen Hosp, Dept Pediat, Tokyo, Japan

[23] Showa Gen Hosp, Dept Infect Dis, Tokyo, Japan

[24] NATURALI Co Ltd, Tokyo, Japan

来源：

OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 06期

关键词：

COVID-19; SARS-CoV-2; variants; test-negative design; vaccine effectiveness;

D O I：

10.1093/ofid/ofad240

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined). In this multi-center study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent vaccines against symptomatic infection during the BA.5-dominant period was high compared to no vaccination (65%/76%) and moderate compared to monovalent vaccines >6 months before (46% combined).

引用

页数：6

共 50 条

[1] Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
Ackerson, Bradley K.
Bruxvoort, Katia J.
Qian, Lei
Sy, Lina S.
Qiu, Sijia
Tubert, Julia E.
Lee, Gina S.
Ku, Jennifer H.
Florea, Ana
Luo, Yi
Bathala, Radha
Stern, Julie
Choi, Soon K.
Takhar, Harpreet S.
Aragones, Michael
Marks, Morgan A.
Anderson, Evan J.
Zhou, Cindy Ke
Sun, Tianyu
Talarico, Carla A.
Tseng, Hung Fu
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
[2] SARS-CoV-2 Incubation Period during the Omicron BA.5-Dominant Period in Japan
Ogata, Tsuyoshi
Tanaka, Hideo
EMERGING INFECTIOUS DISEASES, 2023, 29 (03) : 595 - 598
[3] SARS-CoV-2 Incubation Period during Omicron BA.5-Dominant Period, Japan Response
Ogata, Tsuyoshi
Tanaka, Hideo
EMERGING INFECTIOUS DISEASES, 2024, 30 (01) : 206 - 207
[4] Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Kopel, Hagit
Nguyen, Van Hung
Boileau, Catherine
Bogdanov, Alina
Winer, Isabelle
Ducruet, Thierry
Zeng, Ni
Bonafede, Mac
Esposito, Daina B.
Martin, David
Rosen, Andrew
van de Velde, Nicolas
Vermund, Sten H.
Gravenstein, Stefan
Mansi, James A.
VACCINES, 2023, 11 (11)
[5] Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Chalkias, Spyros
Whatley, Jordan L.
Eder, Frank
Essink, Brandon
Khetan, Shishir
Bradley, Paul
Brosz, Adam
Mcghee, Nichole
Tomassini, Joanne E.
Chen, Xing
Zhao, Xiaoping
Sutherland, Andrea
Shen, Xiaoying
Girard, Bethany
Edwards, Darin K.
Feng, Jing
Zhou, Honghong
Walsh, Stephen
Montefiori, David C.
Baden, Lindsey R.
Miller, Jacqueline M.
Das, Rituparna
NATURE MEDICINE, 2023, 29 (9) : 2325 - 2333
[6] Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Spyros Chalkias
Jordan L. Whatley
Frank Eder
Brandon Essink
Shishir Khetan
Paul Bradley
Adam Brosz
Nichole McGhee
Joanne E. Tomassini
Xing Chen
Xiaoping Zhao
Andrea Sutherland
Xiaoying Shen
Bethany Girard
Darin K. Edwards
Jing Feng
Honghong Zhou
Stephen Walsh
David C. Montefiori
Lindsey R. Baden
Jacqueline M. Miller
Rituparna Das
Nature Medicine, 2023, 29 : 2325 - 2333
[7] Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Tseng, Hung Fu
Ackerson, Bradley K.
Bruxvoort, Katia J.
Sy, Lina S.
Tubert, Julia E.
Lee, Gina S.
Ku, Jennifer H.
Florea, Ana
Luo, Yi
Qiu, Sijia
Choi, Soon Kyu
Takhar, Harpreet S.
Aragones, Michael
Paila, Yamuna D.
Chavers, Scott
Talarico, Carla A.
Qian, Lei
NATURE COMMUNICATIONS, 2023, 14 (01)
[8] Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Hung Fu Tseng
Bradley K. Ackerson
Katia J. Bruxvoort
Lina S. Sy
Julia E. Tubert
Gina S. Lee
Jennifer H. Ku
Ana Florea
Yi Luo
Sijia Qiu
Soon Kyu Choi
Harpreet S. Takhar
Michael Aragones
Yamuna D. Paila
Scott Chavers
Carla A. Talarico
Lei Qian
Nature Communications, 14
[9] Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
Qu, Panke
Faraone, Julia N.
Evans, John P.
Zheng, Yi-Min
Yu, Lianbo
Ma, Qin
Carlin, Claire
Lozanski, Gerard
Saif, Linda J.
Oltz, Eugene M.
Gumina, Richard J.
Liu, Shan-Lu
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (14): : 1329 - 1331
[10] Implications of the SARS-CoV-2 subvariants BA.4 and BA.5
Rahimi, Farid
Abadi, Amin Talebi Bezmin
INTERNATIONAL JOURNAL OF SURGERY, 2022, 104

← 1 2 3 4 5 →